SCHEMBL32669385

SCHEMBL32669385

COC(=O)c1cc(Cl)c(Br)c(F)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.44
GAA P10253 1/20 0.43
MAPT P10636 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 2/20 0.39
ALDH1A1 P00352 1/20 0.39
ABL1 P00519 1/20 0.38
HTT P42858 1/20 0.38
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
MYC P01106 1/20 0.35
CASP3 P42574 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636921 0.83 GAA (0.49) SOS1GAAMAPTNPSR1SMN1; SMN2
SCHEMBL32669393 0.80 SOS1 (0.45) SOS1GAAMAPTNPSR1SMN1; SMN2
SCHEMBL27214471 0.79 SOS1 (0.46) SOS1GAAMAPTNPSR1SMN1; SMN2
SCHEMBL23513343 0.78 GAA (0.46) SOS1GAAMAPTSMN1; SMN2HPGD
SCHEMBL29192851 0.78 SOS1 (0.51) SOS1GAAMAPTNPSR1SMN1; SMN2
SCHEMBL29570775 0.78 SOS1 (0.51) SOS1GAAMAPTNPSR1SMN1; SMN2
SCHEMBL26794168 0.78 SOS1 (0.40) SOS1GAASMN1; SMN2HPGDALDH1A1
SCHEMBL18164140 0.77 GAA (0.50) GAAMAPTNPSR1HPGDALDH1A1
SCHEMBL31267332 0.77 SOS1 (0.38) SOS1GAAMAPTNPSR1HPGD
SCHEMBL23512993 0.77 GAA (0.45) SOS1GAAMAPTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034126-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034126-A1 KRAS INHIBITORS KRAS, NRAS, HRAS SOS1 23/4885GAA 4419/4885MAPT 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.